Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1080/07357907.2021.1885596

http://scihub22266oqcxt.onion/10.1080/07357907.2021.1885596
suck pdf from google scholar
33534645!ä!33534645

suck abstract from ncbi


Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534

Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
pmid33534645      Cancer+Invest 2021 ; 39 (3): 205-213
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Challenges and Opportunities for COVID-19 Vaccines in Patients with Cancer #MMPMID33534645
  • Kuderer NM; Hill JA; Carpenter PA; Lyman GH
  • Cancer Invest 2021[Mar]; 39 (3): 205-213 PMID33534645show ga
  • Given the rapidly expanding global spread of the SARS-Co-V-2 virus and the expanding number of individuals with the serious and potentially fatal illness, COVID-19, there is an urgent need for safe and effective vaccines. Based on compelling evidence that patients with cancer are at increased risk for greater morbidity and mortality with COVID-19, several professional organizations have provided early guidance on the role of COVID-19 vaccines in patients with malignant disease. In this commentary we review the available data on the efficacy and safety of the approved and forthcoming vaccines in patients with cancer. Based on a review of the totality of available evidence, we recommend that most patients with cancer should receive the recommended dose and schedule of one of the COVID-19 vaccines when available. We encourage industry, regulators and professional research organizations to carefully track the efficacy and safety of COVID-19 vaccination in patients with cancer in the real world setting and routinely report unanticipated adverse events and signs of loss of efficacy. Particular attention is needed for patients on active cancer therapy to carefully evaluate efficacy and safety in relationship to the timing of vaccination relative to that of active cancer treatment and immunosuppression.
  • |*Neoplasms/immunology/mortality/therapy/virology[MESH]
  • |2019-nCoV Vaccine mRNA-1273[MESH]
  • |BNT162 Vaccine[MESH]
  • |COVID-19 Vaccines/administration & dosage/*adverse effects/*pharmacology[MESH]
  • |COVID-19/mortality/prevention & control[MESH]
  • |Humans[MESH]
  • |Intensive Care Units[MESH]
  • |Mortality[MESH]
  • |Practice Guidelines as Topic[MESH]
  • |Time Factors[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box